Med BioGene Withdraws IPO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Med BioGene has withdrawn its planned initial public offering in the US, the Canadian personalized diagnostics firm said in a document filed with the US Securities and Exchange Commission last week.

In the filing, Med BioGene said it decided not to pursue its IPO "due to the availability of other opportunities" that its board "deemed to be in the best interests of the company and its shareholders." It did not provide further details.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.